The Scottsdale, Arizona-based radiology practice issued a notice to impacted parties on March 28 after reports of the hack first started surfacing in mid-February.
Michael Reardon, MD, presents late-breaking data comparing TAVR to SAVR in low-risk patients after five years.
Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.
There are at least 65 consolidated cases pending in federal courts that stem from the 2024 data breach on the claims processor's network. A judge in Minnesota has asked that the lawsuits be coordinated and consolidated as much as possible.
Darren K. McGuire, MD, a professor of medicine at UT Southwestern Medical Center, presents late-breaking clinical data on the cardiovascular benefits of oral semaglutide during ACC.25 in Chicago.
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
Cardiologist Marc P. Bonaca, MD, presents the STRIDE late-breaking clinical trial at ACC.25 in Chicago.
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.
